Spruce Biosciences Inc (SPRB)

09:13 AM

Spruce Biosciences Inc (SPRB) Stock: Uncovering 52-Week Market Trends - investchronicle.com

09:13 AM

Apr 24, 2025

Citizens JMP maintains Market Perform on Spruce Biosciences By Investing.com - Investing.com Nigeria

Apr 24, 2025

Apr 23, 2025

Citizens JMP maintains Market Perform on Spruce Biosciences - Investing.com

Apr 23, 2025

Apr 22, 2025

The Potential Rise in the Price of Spruce Biosciences Inc (SPRB) following insiders activity - knoxdaily.com

Apr 22, 2025

Apr 22, 2025

TD Cowen reiterates NextDecade Corporation (NEXT) stock to a Buy - knoxdaily.com

Apr 22, 2025

Apr 19, 2025

Q1 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World

Apr 19, 2025

Apr 19, 2025

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $2.17 Consensus Target Price from Analysts - Defense World

Apr 19, 2025

Apr 17, 2025

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript - Insider Monkey

Apr 17, 2025

Apr 17, 2025

Spruce Biosciences Inc (NASDAQ: SPRB) Slashes -6.82%: What Could Be On The Way Going Forward? - stocksregister.com

Apr 17, 2025

Apr 17, 2025

Spruce Bio sows the seeds of its new future - pharmaphorum

Apr 17, 2025

Apr 17, 2025

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com

Apr 17, 2025

Apr 16, 2025

Spruce Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 16, 2025

Apr 16, 2025

RBC Cuts Price Target on Spruce Biosciences to $0.50 From $1.50, Keeps Sector Perform, Speculative Risk - marketscreener.com

Apr 16, 2025

Apr 16, 2025

Spruce Biosciences Announces New Corporate Strategy and Acquisit - GuruFocus

Apr 16, 2025

Apr 15, 2025

SPRB stock touches 52-week low at $0.18 amid market challenges By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Spruce Biosciences plans BLA for rare disease therapy By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals

Apr 15, 2025

Apr 15, 2025

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com

Apr 15, 2025

Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 15, 2025

Apr 15, 2025

Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com

Apr 15, 2025

Apr 15, 2025

Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga

Apr 15, 2025

Apr 15, 2025

SPRB stock touches 52-week low at $0.18 amid market challenges - Investing.com Canada

Apr 15, 2025

Apr 15, 2025

Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga

Apr 15, 2025

Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025

Apr 15, 2025

Spruce Biosciences (SPRB) Acquires New Therapy for Rare Disease Treatment | SPRB Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Spruce Biosciences plans BLA for rare disease therapy - Investing.com Australia

Apr 15, 2025

Apr 15, 2025

SPRUCE BIOSCIENCES, INC. SEC 10-K Report - TradingView

Apr 15, 2025

Apr 15, 2025

Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa - MarketScreener

Apr 15, 2025

Apr 15, 2025

Major Rare Disease Breakthrough: Spruce Bio Secures Promising Treatment for Fatal Childhood Disease - Stock Titan

Apr 15, 2025

Apr 11, 2025

Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace

Apr 11, 2025

Apr 08, 2025

Levi & Korsinsky Reminds Shareholders of an Investigation into Spruce Biosciences, Inc. (SPRB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire

Apr 08, 2025

Apr 07, 2025

SPRB stock touches 52-week low at $0.26 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

SPRB stock touches 52-week low at $0.26 amid market challenges - Investing.com India

Apr 07, 2025

Apr 07, 2025

Congenital Adrenal Hyperplasia Treatment Market: Key Trends, - openPR.com

Apr 07, 2025

Apr 01, 2025

Spruce Biosciences reports delayed annual filing By Investing.com - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

Spruce Biosciences reports delayed annual filing - Investing.com

Apr 01, 2025

Mar 31, 2025

Spruce Biosciences Delays Annual Report Filing - TipRanks

Mar 31, 2025

Mar 31, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 31, 2025

Mar 25, 2025

Spruce Biosciences stock hits 52-week low at $0.32 - Investing.com

Mar 25, 2025

Mar 25, 2025

In-Depth Analysis Of The Global Congenital Adrenal Hyperplasia Market: Key Drivers, Trends, Growth Opportun... - WhaTech

Mar 25, 2025

Mar 25, 2025

Spruce Biosciences stock hits 52-week low at $0.32 By Investing.com - Investing.com Canada

Mar 25, 2025

Mar 22, 2025

SPRUCE BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 22, 2025

Mar 20, 2025

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 20, 2025

Mar 14, 2025

Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at $2.38 - Defense World

Mar 14, 2025

Mar 12, 2025

SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline - Investing.com India

Mar 12, 2025

Mar 11, 2025

Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025